Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroMetrix, Inc.

Full company profile

uuid00yplki

Namestring
NeuroMetrix, Inc.
Legal namestring
NeuroMetrix, Inc.
Websiteurl
neurometrix.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

NeuroMetrix, Inc. is a U.S.-based medical device company that develops and commercializes non-invasive neurotechnology for the diagnosis and treatment of pain and neurological disorders. The company's core product is the Quell® Fibromyalgia system, a thin, wearable neuromodulation device worn on the upper calf that delivers electrical stimulation to sensory nerves. Quell is powered by a proprietary custom-designed microchip that enables flexible, high-power nerve stimulation in a credit-card-sized form factor, uses onboard position and motion sensing to auto-adjust therapy, and pairs via Bluetooth low energy with iOS and Android companion apps for personalized therapy management, sleep tracking, and severity monitoring. Quell is the first and only FDA-authorized medical device specifically indicated to help reduce fibromyalgia symptoms and is covered by 27 issued U.S. utility patents.

NeuroMetrix operates a hybrid hardware-plus-consumable business model: it sells the Quell device hardware directly to consumers through its own e-commerce storefront and generates the majority of its revenue from recurring aftermarket sales of proprietary disposable electrodes that are required to operate the device. Distribution is direct-to-consumer under the Quell brand, with customer service support via phone and email, and the company claims a cumulative installed reach of more than 5 million users across its healthcare products worldwide.

The company is now a wholly-owned subsidiary of electroCore, Inc., having been absorbed into a larger neurotechnology platform. Headcount is reported at 11–50 employees and the corporate office is located at 200 Forge Way, Suite 205, Rockaway, New Jersey. No revenue figures, funding rounds, or material expansion activity are disclosed in the available source materials.

Short descriptiontext

NeuroMetrix develops the Quell Fibromyalgia wearable neurostimulation device, the first FDA-authorized medical device for reducing fibromyalgia symptoms, and sells it direct-to-consumer globally with recurring revenue from proprietary consumable electrodes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockaway, United States
HQ citystring
Rockaway
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable neurostimulation devices, fibromyalgia pain management, non-invasive neuromodulation, medical nerve stimulation, neurological therapeutic devices
Industry2 codes
PRIMARYCRACAQAK
Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Neuromodulation Devices
Social media profiles1 record
Revenue model2 records
1Device Sales
TypeHardware Sales
Description

Sale of the Quell Fibromyalgia wearable medical device hardware.

neurometrix.com
2Consumable Aftermarket Sales
TypeSubscription Recurring
Description

The majority of revenue is generated by aftermarket sales of proprietary consumables (disposable electrodes). This creates recurring revenue from the installed device base.

neurometrix.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Quell® Fibromyalgia
Description

Advanced, non-invasive, nerve stimulation device that is the first and only FDA authorized medical device that helps reduce the symptoms of fibromyalgia. It is a thin wearable medical device inserted into a soft band, placed on the upper calf, that comfortably stimulates sensory nerves.

neurometrix.com
Core offering1 text field

NeuroMetrix develops, manufactures, and sells the Quell® Fibromyalgia wearable neuromodulator, an FDA-authorized, non-invasive medical device that delivers transcutaneous electrical nerve stimulation to the upper calf to reduce fibromyalgia symptoms. The product is sold directly to patients and pairs with a smartphone app for dose customization, with recurring revenue from replacement electrode consumables.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Majority of participants reported improvement in pain with regular use in 60-day home use test among 88 Quell users
Product overview1 text field

NeuroMetrix offers a unified product ecosystem centered on the Quell® Fibromyalgia system, which combines a wearable neuromodulation hardware device with a companion mobile app and proprietary consumable electrodes. The company develops non-invasive medical devices for pain and neurological disorder diagnosis and treatment, with the majority of revenue generated by aftermarket consumable sales. Over 5 million people worldwide have benefited from NeuroMetrix products.

Product and service3 records
1Quell® Fibromyalgia
CategoryWearable Neuromodulation Devices
Description

An FDA-authorized, non-invasive wearable neuromodulator placed on the upper calf that delivers transcutaneous electrical nerve stimulation to reduce fibromyalgia pain and improve sleep. It is targeted at adult consumers diagnosed with fibromyalgia who want an at-home, drug-free therapy, and pairs with a smartphone app for dose personalization and therapy tracking.

2Quell Fibromyalgia App
CategoryCompanion Mobile Application
Description

Companion mobile application that communicates with the Quell® Fibromyalgia device over Bluetooth Low Energy to start/stop therapy, customize dose, track sleep, and reorder replacement electrodes. It is intended for the same fibromyalgia patient who uses the Quell device.

3Quell Replacement Electrodes
CategoryMedical Device Consumables
Description

Aftermarket disposable electrode consumables used with the Quell® Fibromyalgia wearable neuromodulator, purchased on a recurring basis by existing Quell users to keep the device functional.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cala Health markets Cala Trio, a wearable transcutaneous peripheral nerve stimulation device for essential tremor; it is the closest direct comparable to NeuroMetrix's Quell as a prescription-grade wearable TENS-style neurostimulator sold to chronic-condition patients.

TypeBroad incumbent
Description

Inspire is an implantable neurostimulation company for obstructive sleep apnea; comparable as a neuromodulation pure-play with FDA-authorized technology, a chronic-condition patient focus, and recurring implant/replacement economics.

3Axonics, Inc.
TypeBroad incumbent
Description

Axonics develops implantable sacral and pudendal neuromodulation systems for incontinence; comparable as a neuromodulation device company focused on chronic-condition patients with an FDA-cleared, recurring-revenue consumables model (rechargeable IPG).

TypeBroad incumbent
Description

Nevro markets the Senza spinal cord stimulation system for chronic pain; comparable as an established neuromodulation device company addressing chronic neuropathic pain with FDA-cleared technology and recurring implant revenue.

TypeDirect peer
Description

DyAnsys produces wearable neurostimulators (e.g., DrugRelief, Primary Relief) for pain and opioid-sparing applications; a direct peer as a small wearable-electrical-neurostimulation device company targeting chronic pain.

TypeBroad incumbent
Description

Medtronic operates one of the broadest neuromodulation portfolios (spinal cord, deep brain, sacral, peripheral nerve stimulation); comparable as a broad incumbent in the same medical-device neuromodulation category where Quell competes.

7iReliev (ExcelHealth)
TypeDirect peer
Description

iReliev markets a range of OTC TENS/EMS combination units for pain relief and muscle recovery; comparable as a DTC-focused consumer TENS competitor with overlapping electrode-based recurring consumable economics.

TypeDirect peer
Description

SPR Therapeutics commercializes peripheral nerve stimulation systems for chronic and acute pain; comparable to NeuroMetrix in the percutaneous/wearable nerve stimulation category for chronic pain management, with overlapping call points in pain specialists.

TypeBroad incumbent
Description

NeuroMetrix's parent company and a developer of non-invasive vagus nerve stimulation (gammaCore) for migraine and other conditions; directly comparable as a non-invasive neuromodulation commercial-stage company, though with a different nerve target and indication focus.

10Omron Healthcare
TypeDirect peer
Description

Omron sells consumer TENS/EMS pain-relief devices (e.g., Avail, PocketPain Pro) direct-to-consumer; comparable as a mass-market consumer-electronics TENS competitor to Quell in the same purchase channel.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroMetrix, Inc.

Wearable Neuromodulation Devicesneurometrix.com

NeuroMetrix develops the Quell Fibromyalgia wearable neurostimulation device, the first FDA-authorized medical device for reducing fibromyalgia symptoms, and sells it direct-to-consumer globally with recurring revenue from proprietary consumable electrodes.

What NeuroMetrix, Inc. does

NeuroMetrix, Inc. is a U.S.-based medical device company that develops and commercializes non-invasive neurotechnology for the diagnosis and treatment of pain and neurological disorders. The company's core product is the Quell® Fibromyalgia system, a thin, wearable neuromodulation device worn on the upper calf that delivers electrical stimulation to sensory nerves. Quell is powered by a proprietary custom-designed microchip that enables flexible, high-power nerve stimulation in a credit-card-sized form factor, uses onboard position and motion sensing to auto-adjust therapy, and pairs via Bluetooth low energy with iOS and Android companion apps for personalized therapy management, sleep tracking, and severity monitoring. Quell is the first and only FDA-authorized medical device specifically indicated to help reduce fibromyalgia symptoms and is covered by 27 issued U.S. utility patents.

NeuroMetrix operates a hybrid hardware-plus-consumable business model: it sells the Quell device hardware directly to consumers through its own e-commerce storefront and generates the majority of its revenue from recurring aftermarket sales of proprietary disposable electrodes that are required to operate the device. Distribution is direct-to-consumer under the Quell brand, with customer service support via phone and email, and the company claims a cumulative installed reach of more than 5 million users across its healthcare products worldwide.

The company is now a wholly-owned subsidiary of electroCore, Inc., having been absorbed into a larger neurotechnology platform. Headcount is reported at 11–50 employees and the corporate office is located at 200 Forge Way, Suite 205, Rockaway, New Jersey. No revenue figures, funding rounds, or material expansion activity are disclosed in the available source materials.

NeuroMetrix, Inc. firmographics

Firmographics
Name
NeuroMetrix, Inc.
Legal name
NeuroMetrix, Inc.
Website
https://neurometrix.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuroMetrix develops the Quell Fibromyalgia wearable neurostimulation device, the first FDA-authorized medical device for reducing fibromyalgia symptoms, and sells it direct-to-consumer globally with recurring revenue from proprietary consumable electrodes.
Ownership category
akta.pro rank

NeuroMetrix, Inc. industry classification

Industry
Product category
Wearable Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYCRACAQAK
Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Wearable neurostimulation devices
  • Fibromyalgia pain management
  • Non-invasive neuromodulation
  • Medical nerve stimulation
  • Neurological therapeutic devices

Where NeuroMetrix, Inc. is headquartered

Location

Headquarters

HQ city
Rockaway
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuroMetrix, Inc. business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

  1. Device Sales: Sale of the Quell Fibromyalgia wearable medical device hardware.
  2. Consumable Aftermarket Sales: The majority of revenue is generated by aftermarket sales of proprietary consumables (disposable electrodes). This creates recurring revenue from the installed device base.

Distribution channels1 record

NeuroMetrix, Inc. product offering

Product offering

Core offering

NeuroMetrix develops, manufactures, and sells the Quell® Fibromyalgia wearable neuromodulator, an FDA-authorized, non-invasive medical device that delivers transcutaneous electrical nerve stimulation to the upper calf to reduce fibromyalgia symptoms. The product is sold directly to patients and pairs with a smartphone app for dose customization, with recurring revenue from replacement electrode consumables.

Product overview

NeuroMetrix offers a unified product ecosystem centered on the Quell® Fibromyalgia system, which combines a wearable neuromodulation hardware device with a companion mobile app and proprietary consumable electrodes. The company develops non-invasive medical devices for pain and neurological disorder diagnosis and treatment, with the majority of revenue generated by aftermarket consumable sales. Over 5 million people worldwide have benefited from NeuroMetrix products.

Differentiator

Problem solved

Functional benefit

Brands

  • Quell® Fibromyalgia: Advanced, non-invasive, nerve stimulation device that is the first and only FDA authorized medical device that helps reduce the symptoms of fibromyalgia. It is a thin wearable medical device inserted into a soft band, placed on the upper calf, that comfortably stimulates sensory nerves.

Products and services

  • Quell® Fibromyalgia An FDA-authorized, non-invasive wearable neuromodulator placed on the upper calf that delivers transcutaneous electrical nerve stimulation to reduce fibromyalgia pain and improve sleep. It is targeted at adult consumers diagnosed with fibromyalgia who want an at-home, drug-free therapy, and pairs with a smartphone app for dose personalization and therapy tracking.
  • Quell Fibromyalgia App Companion mobile application that communicates with the Quell® Fibromyalgia device over Bluetooth Low Energy to start/stop therapy, customize dose, track sleep, and reorder replacement electrodes. It is intended for the same fibromyalgia patient who uses the Quell device.
  • Quell Replacement Electrodes Aftermarket disposable electrode consumables used with the Quell® Fibromyalgia wearable neuromodulator, purchased on a recurring basis by existing Quell users to keep the device functional.

Quantifiable outcome

  • Majority of participants reported improvement in pain with regular use in 60-day home use test among 88 Quell users

Companies that use NeuroMetrix, Inc.

Customer profile

Segments1 record

Ideal customer profiles1 record

NeuroMetrix, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NeuroMetrix, Inc. partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights4 records

NeuroMetrix, Inc. competitors and assessment

Company assessment

Direct peers

  • Cala Health: Cala Health markets Cala Trio, a wearable transcutaneous peripheral nerve stimulation device for essential tremor; it is the closest direct comparable to NeuroMetrix's Quell as a prescription-grade wearable TENS-style neurostimulator sold to chronic-condition patients.
  • DyAnsys: DyAnsys produces wearable neurostimulators (e.g., DrugRelief, Primary Relief) for pain and opioid-sparing applications; a direct peer as a small wearable-electrical-neurostimulation device company targeting chronic pain.
  • iReliev (ExcelHealth): iReliev markets a range of OTC TENS/EMS combination units for pain relief and muscle recovery; comparable as a DTC-focused consumer TENS competitor with overlapping electrode-based recurring consumable economics.
  • SPR Therapeutics: SPR Therapeutics commercializes peripheral nerve stimulation systems for chronic and acute pain; comparable to NeuroMetrix in the percutaneous/wearable nerve stimulation category for chronic pain management, with overlapping call points in pain specialists.
  • Omron Healthcare: Omron sells consumer TENS/EMS pain-relief devices (e.g., Avail, PocketPain Pro) direct-to-consumer; comparable as a mass-market consumer-electronics TENS competitor to Quell in the same purchase channel.

Broad incumbents

  • Inspire Medical Systems: Inspire is an implantable neurostimulation company for obstructive sleep apnea; comparable as a neuromodulation pure-play with FDA-authorized technology, a chronic-condition patient focus, and recurring implant/replacement economics.
  • Axonics, Inc. Axonics develops implantable sacral and pudendal neuromodulation systems for incontinence; comparable as a neuromodulation device company focused on chronic-condition patients with an FDA-cleared, recurring-revenue consumables model (rechargeable IPG).
  • Nevro Corp. Nevro markets the Senza spinal cord stimulation system for chronic pain; comparable as an established neuromodulation device company addressing chronic neuropathic pain with FDA-cleared technology and recurring implant revenue.
  • Medtronic plc: Medtronic operates one of the broadest neuromodulation portfolios (spinal cord, deep brain, sacral, peripheral nerve stimulation); comparable as a broad incumbent in the same medical-device neuromodulation category where Quell competes.
  • electroCore, Inc. NeuroMetrix's parent company and a developer of non-invasive vagus nerve stimulation (gammaCore) for migraine and other conditions; directly comparable as a non-invasive neuromodulation commercial-stage company, though with a different nerve target and indication focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NeuroMetrix, Inc. social profiles

Digital presence

NeuroMetrix, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroMetrix, Inc. leadership team

Management profile

Number of profiles

NeuroMetrix, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroMetrix, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroMetrix, Inc.

What does NeuroMetrix, Inc. do?

NeuroMetrix develops, manufactures, and sells the Quell® Fibromyalgia wearable neuromodulator, an FDA-authorized, non-invasive medical device that delivers transcutaneous electrical nerve stimulation to the upper calf to reduce fibromyalgia symptoms. The product is sold directly to patients and pairs with a smartphone app for dose customization, with recurring revenue from replacement electrode consumables.

Is NeuroMetrix, Inc. a public or private company?

NeuroMetrix, Inc. is a private company. It is classified as corporate owned and is currently operating.

When was NeuroMetrix, Inc. founded?

NeuroMetrix, Inc. was founded in 1996. It employs 11 to 50 people.

Where is NeuroMetrix, Inc. based?

NeuroMetrix, Inc. is headquartered in Rockaway, United States, in the North America region.

How does NeuroMetrix, Inc. make money?

Two revenue lines are on record. Device Sales are the primary driver. The others are consumable Aftermarket Sales.

Who are NeuroMetrix, Inc.'s main competitors?

Direct peers on record are Cala Health, DyAnsys, iReliev (ExcelHealth), SPR Therapeutics and Omron Healthcare. Broad incumbents are Inspire Medical Systems, Axonics, Inc., Nevro Corp., Medtronic plc and electroCore, Inc..

Does NeuroMetrix, Inc. have an API?

No public API is recorded for NeuroMetrix, Inc..

What industry is NeuroMetrix, Inc. in?

NeuroMetrix, Inc.'s product category is Wearable Neuromodulation Devices. Its primary akta.pro industry code is CRACAQAK, Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNerve Repair and Regeneration Market worth $12.64 billion by 2031 - Exclusive Report by MarketsandMarkets™The nerve repair and regeneration market is projected to grow from $8.06 billion in 2026 to $12.64 billion by 2031, a CAGR of 9.42%. North America led with a 40% share in 2025, and neurostimulation devices held 86.2% of the product segment. Asia Pacific is expected to see the highest growth rate.openPR.comNeuromodulation Market Report Examines Industry Trends, Growth Drivers And Future OutlookThe Business Research Company released a market report projecting the neuromodulation industry will grow to $12.88 billion by 2030, with an 11.1% compound annual growth rate, driven by AI-assisted systems, home-based therapies, and advancements in biomaterials and device miniaturization. In December 2024, electroCore Inc. acquired NeuroMetrix Inc. to strengthen its wearable neuromodulation portfolio for chronic pain management by integrating NeuroMetrix's Quell platform. In July 2023, Boston Scientific Corporation received FDA clearance for its Vercise Neural Navigator 5 software supporting the fourth-generation Vercise Genus Deep Brain Stimulation System for Parkinson's disease and essential tremor patients.openPR.comAnalysis of Key Market Segments Driving the Non Invasive Neurostimulation Devices IndustryThe Business Research Company released a market analysis projecting the non-invasive neurostimulation devices market will grow to $3.45 billion by 2030, with a compound annual growth rate of 12.7%, driven by advancements in tDCS and EMS technologies, rising chronic pain and neurological disorder prevalence, and increased homecare adoption. In December 2024, ElectroCore Inc. acquired NeuroMetrix Inc., expanding its portfolio in non-invasive neuromodulation with the addition of Quell pain relief and DPNCheck diagnostic devices. The analysis identifies key industry players and trends including personalized stimulation protocols and remote clinician-monitored treatment systems.openPR.comMuscle Stimulator Market Statistical Forecast, Trade Analysis 2024 -Omron Corporation, R.S. Medical Inc., Neurometrix Inc., Zynex Inc.DataM Intelligence published a market research report on the global muscle stimulator market, covering key players, segments, and regional analysis. The report projects a CAGR of 3.9% from 2024 to 2031, with growth driven by adoption of strategies by major players.YahooNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearNeuroMetrix's CEO Shai Gozani will face shareholder scrutiny at the April 30 AGM, with his 2023 total pay of $476k down 26% from 2022. The company's EPS fell 19% over three years and shareholder return was -82% in that period, suggesting shareholders may reject a pay raise.BenzingaMid-Afternoon Market Update: Dow Jumps Over 600 Points; NeuroMetrix Shares Spike Higher - Ardelyx (NASDAQOn Tuesday, U.S. stock markets saw significant gains, with the Dow climbing 1.83% to 34,583.56. HCA Healthcare, Inc. experienced a notable increase of 15% after reporting better-than-expected Q2 results, while NeuroMetrix, Inc. shares spiked 152% following FDA Breakthrough Designation for its device aimed at treating fibromyalgia symptoms.Benzinga52 Stocks Moving In Tuesday's Mid-Day Session - Agios Pharmaceuticals (NASDAQ:AGIO), Arcturus TherapeuticCuris, Inc. (NASDAQ:CRIS) stock surged 323% following the announcement of positive preliminary data from a Phase 1 study of CA-4948 monotherapy in leukemia and myelodysplastic syndromes. Multiple companies, including NeuroMetrix, Inc. (NASDAQ:NURO) and Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), also experienced significant stock increases due to better-than-expected quarterly results or upgrades from analysts. The overall activity reflects heightened investor interest and movement within the biotech sector, as several companies reported notable stock gains.PR NewswireGlobal Non-Opioid Pain Relief Device Market to Reach $8.8 Billion by 2029BIS Research projects the global non-opioid pain relief device market will grow from $3.7 billion in 2018 to $8.8 billion by 2029, driven by rising chronic pain cases and regulatory concerns regarding opioid side effects. Abbott Laboratories currently holds the largest market share, while Neurometrix Inc. leads in wearable TENS technology within the electroanalgesia segment. The report highlights North America as the dominant region and Asia-Pacific as the fastest-growing market during the forecast period.PR NewswireSmart Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024Reportlinker published a market research report covering the global smart medical devices market from 2016 to 2024, providing analysis on market size, segmentation by product type, modality, and end users, along with growth trends across geographic regions. The report profiles key market players including Abbott Laboratories, Apple Inc., Dexcom, Inc., Fitbit, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Medtronic plc, NeuroMetrix, Inc., Samsung Electronics Co., Ltd, and Sonova, analyzing their market share and business strategies. The market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.